Archimmune Therapeutics, Inc.

Archimmune is an immuno-oncology platform company. Its first program is aimed at developing standardized antigen capturing nanoparticles that form a personalized, systemically-acting cancer vaccine in situ when injected intra-tumorally following radiotherapy. The second program exploits the ability of nanocarriers to simultaneously and bi-/tri-specifically engage with selected tumor and/or IO targets.